Empagliflozin as metabolically active compound for treatment of non-alcoholic fatty liver disease in type 2 diabetes S. Kahl,S. Gancheva,K. Strassburger, C. Herder,J. Machann, Y. Kupriyanova,S. Kabisch, E. Henkel,K. Kantartzis,S. Kopf, C. Kasperk,N. Stefan, A. Pfeiffer,A. L. Birkenfeld,M. RodenDIABETOLOGIA(2019)引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要